Protection against infectious
laryngotracheitis powered by VAXXITEK®
The
POWER to
PROTECT
uniquely and conveniently
A strong immune foundation and optimized protection against Marek's diease, infectious bursal disease, and infectious laryngotracheitis in one shot.
VAXXITEK® HVT+IBD+ILT
PROTECT FLOCKS IN THE HATCHERY WITH A 3-IN-1 SOLUTION
3 in 1
Precision engineered
Building on the trusted vaccination platform used to develop VAXXITEK® HVT+IBD, our research and manufacturing experts successfully designed a 3-in-1 vaccine that provides a strong immune foundation and optimizes protection against Marek’s disease (MD), infectious bursal disease (IBD)—and infectious laryngotracheitis (ILT).
It all starts with the same bioengineering platform as the original Vaxxitek® HVT+IBD in order to capture it's recognized benefits. Next, the immunogenic glycoprotein D ILT is inserted for optimal ILT protection. This unique vector vaccine has a single promoter for 2 disease inserts (IBD and ILT), which leads to consistent antigen expression and immunity.1
- All the benefits of VAXXITEK® HVT+IBD now with the power of ILT protection
- Simplified vaccination program: from field to hatchery
- Developed by the trusted leader in IBD vector vaccine technology
- Proven safety for your flock
Key advantages
- A single vaccination to protect against MD, IBD and ILT1
- Engineered using the same backbone as VAXXITEK® HVT+IBD
- Demonstrated safety proven by clinical studies1
- Immunogenic glycoprotein D ILT insert for optimal ILT protection
- Protects efficiently against both classic and variant E IBDV1
- Subcutaneous or in ovo administration of VAXXITEK® HVT+IBD+ILT provides reliable ILT protection1
- Onset of immunity against MD shown from 5 days of age1
PRODUCT RESOURCES
🗎 Download SDS
🗎 Download Sales Aid
▹ Watch VAXXITEK® HVT+IBD+ILT Video
▹ Watch Technical Video
CONTACT INFORMATION
Boehringer Ingelheim Animal Health Canada Inc.
Poultry Business Unit
5180 S Service Rd. Burlington, ON L7L 5H4
Customer Care: 1-800-567-1885
- 3-in-1 vaccine: MD, IBD, and ILT protection
- The strong immune foundation provided by the VAXXITEK® HVT+IBD backbone enables productivity, reduces antibiotic use, and supports return on investment2–8
- Same VAXXITEK® technology platform ensures proper gene expression
- Improved animal welfare through fewer vaccine applications1
- Moving vaccination from field to hatchery reduces chick-handling stress
- Reduced labor, time, and cost enable increased profitability
- Safe and easy to use
- Package in 5 x 2,000 dose ampules in frozen presentation
- BIAH code: 163752
- Package in 5 x 4,000 dose ampules in frozen presentation
- BIAH code: 163753
- Do not mix with other products, except as specified on the label
- In case of human exposure, contact a physician
- Administer only as recommended
- Use entire contents when first opened
- Do not vaccinate within 21 days before slaughter
- Contains penicillin and streptomycin sulfate, which are added as bacteriostatic agents
- Contains amphotericin B as a fungistatic agent
- Inactivate unused contents before disposal
- Safety comparable to existing HVT vector vaccines9
- Proven to remain safe and stable; will not revert to virulence10
- As a live vaccine, the vaccine strain is excreted from vaccinated birds and may spread to turkeys. Safety trials have shown that the strain is safe for turkeys. However, precautionary measures have to be followed in order to avoid direct or indirect contact between vaccinated chickens and turkeys.
References: 1. Data on file. Boehringer Ingelheim Animal Health. 2. Morton DB. Vaccines and animal welfare. Rev Sci Tech. 2007;26:157–163. 3. Lemiere S, Rojo F, Fernandez R, et al. Benefits of the herpesvirus of turkey vector vaccine of infectious bursal disease in control of immuno-depression in broilers and decrease of use of antibiotic medication. In: Proceedings from the XVIII Congress of the World Veterinary Poultry Association Congress; August 19–23, 2013; Nantes, France. Abstract. 4. Hoelzer K, Bielke L, Blake DP, et al. Vaccines as alternatives to antibiotics for food producing animals. Part 2: new approaches and potential solutions. Vet Res. 2018;49:70. 5. Atienza JC, Nagera AJ, Martinez PO, et al. Evaluation of a herpesvirus of turkey vector vaccine inducing protection against infectious bursal and Marek’s diseases (VAXXITEK® HVT + IBD) under Philippines field conditions. In: Proceedings from the XXIII World’s Poultry Congress; June 29–July 4, 2008; Queensland, Australia. 6. Rautenschlein S, Lemiere S, Simon B, Prandini F. A comparison of the effects of the humoral and cell-mediated immunity between an HVT-IBD vector vaccine and an IBDV-immune complex vaccine after in ovo vaccination of commercial broilers. In: Proceedings from the XVII Congress of the World Veterinary Poultry Association Congress; August 14–18, 2011; Cancun, Mexico: 830–843. 7. Tang SF, He SJ, Li WM, Lemiere S. Field experience of vaccination in day-old broiler chickens with a herpesvirus turkey-infectious bursal disease (HVT-IBD) vector vaccine in different systems of chicken production across China. Poster presentation. In: Proceedings from the XVII Congress of the World Veterinary Poultry Association Congress; August 14–18, 2011; Cancun, Mexico: 920–926. 8. Zhou X, Wang D, Xiong J, Zhang P, Li Y, She R. Protection of chickens, with or without maternal antibodies, against IBDV infection by a recombinant IBDV-VP2 protein. Vaccine. 2010;28:3990–3996. 9. Merial Select, Inc., 2017. Report number 16-187. 10. Boehringer Ingelheim R&D, 2017. Report number 17.0107.R.
